^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    GNOS-PV02

    i
    Associations
    News

    Trials

    Company:
    Geneos Therap
    Drug class:
    Immunostimulant
    Related drugs:
    Associations
    News

    Trials

    Apply
    GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects with Advanced HCC (GT-30) (NCT04251117)
    Phase 1/2
    Geneos Therapeutics
    Active, not recruiting
    Last update posted :
    01/31/2025
    Initiation :
    03/01/2020
    Primary completion :
    11/29/2024
    Completion :
    11/29/2028
    IFNG
    |
    Keytruda (pembrolizumab) • rocakinogene sifuplasmid (INO-9012) • GNOS-PV02